Cargando…
Achieving high value care for all and the perverse incentives of 340B price agreements
Section 340B of the Public Health Service Act requires drug manufacturers to enter into price agreements with the Department of Health and Human Services. These agreements result in variation in the price paid to acquire a drug by sector, which complicates the price used in cost-effectiveness analys...
Autores principales: | Whittington, Melanie D., Campbell, Jonathan D., McQueen, R. Brett |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914743/ https://www.ncbi.nlm.nih.gov/pubmed/29708214 http://dx.doi.org/10.1212/CPJ.0000000000000437 |
Ejemplares similares
-
Patient and Payer Preferences for Additional Value Criteria
por: Jakab, Ivett, et al.
Publicado: (2021) -
Cellulose Perversions
por: Canejo, João P., et al.
Publicado: (2013) -
Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States
por: Carlson, Josh J., et al.
Publicado: (2019) -
“Perverse Incentives” and the Triple Aim: Overcoming the Troubled Path to Economic Integration for Integrative Medicine and Health
por: Weeks, John
Publicado: (2015) -
Perversions with a twist
por: Silva, Pedro E. S., et al.
Publicado: (2016)